Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Millipore Launches MILLIPLEX® MAP Kits

Published: Tuesday, May 07, 2013
Last Updated: Tuesday, May 07, 2013
Bookmark and Share
Enables detection of multiple pluripotency markers in a single measurement.

Merck Millipore has announced availability of the MILLIPLEX® MAP Human Stem Cell Pluripotency Magnetic Bead Kits, which enable the analysis of many different pluripotency biomarkers in a single measurement.

These kits are the first commercially available multiplexed protein biomarker assays based on the Luminex® xMAP® platform for this important research area.

This new application of trusted bead-based multiplex technology gives researchers rapid feedback on the potency status of stem cell cultures and offers a significant advantage over existing techniques, which detect a limited number of proteins with a semi-quantitative output for a single sample.

Merck Millipore's new MILLIPLEX® MAP kits examine protein biomarkers that indicate the potency of stem cells, enabling pluripotent stem cells to be distinguished from multipotent or differentiating cells.

These new kits save time and resources by accurately detecting large numbers of pluripotency markers in one measurement. Kits can be used on cultures of induced pluripotent stem cells, human embryonic stem cells, cancer stem cells or cancer cell lines.

Two kits are available for assessing stem cell pluripotency. The MILLIPLEX® MAP Human Stem Cell Pluripotency Magnetic Bead Kit 1 monitors the expression of the transcription factors Oct 3/4, Sox2, Nanog and c-Myc, which play critical roles in the maintenance of pluripotency and self-renewal in stem cells.

The MILLIPLEX® MAP Human Stem Cell Pluripotency Magnetic Bead Kit 2 contains seven additional pluripotency-related markers, including a transcription factor, a translational regulator, transmembrane proteins and cell surface glycostructures.

These assays are essential for assessing the potency of stem cell cultures in studies ranging from cancer and developmental biology research to bioprocess monitoring. MILLIPLEX® MAP assays make it easy to analyze both cell surface and intracellular proteins.

"The MILLIPLEX® MAP Stem Cell Pluripotency Kit 1 is a valuable tool for stem cell research. We obtained very interesting and promising results," said Frank Edenhofer, Ph.D., Head of the Stem Cell Engineering Group, Institute of Reconstructive Neurobiology, University of Bonn, LIFE & BRAIN Center. "It is noteworthy that this assay enabled us to observe even early onset of differentiation in iPS cell cultures."

"Stem cells are of great interest for regenerative medicine and drug discovery efforts, and researchers must be able to effectively characterize the potency status of pluripotent stem cells to advance their progress toward clinical use," said Linda Meeh, Ph.D., Director of Marketing for Immunoassays and Multiplexing.

Meeh continued, "MILLIPLEX® MAP kits offer a quick and simple way to achieve this characterization, generating a comprehensive assessment of the overall quality of cell cultures."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore, VWR Extend Western European Distribution Agreement
Provides VWR access to more Merck Millipore products and reagents for chemical and microbiological analysis.
Wednesday, April 09, 2014
Merck Millipore Announces New Genomic Biomarker Services
Genetic and epigenetic technologies added to established CRO services for biomarker development, validation and testing.
Wednesday, December 05, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!